![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Age and Gender Effects on the
Pharmacokinetics of HCV NS5A Inhibitor MK-8742
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
WL Marshall1, WW Yeh1, D Stypinski2, P Auger2, L Caro1, P Jumes1, X Huang1, DP Dreyer1, H-P Feng1, T O'Reilly2, B DeGroot2, T Ward2, and JR Butterton1
1Merck & Co., Inc., Whitehouse Station NJ, USA; 2Celerion, Tempe, AZ, USA
![Pharm1.gif](../images/052514/052514-6/Pharm1.gif)
![Pharm2.gif](../images/052514/052514-6/Pharm2.gif)
![Pharm3.gif](../images/052514/052514-6/Pharm3.gif)
![Pharm4.gif](../images/052514/052514-6/Pharm4.gif)
![Pharm5.gif](../images/052514/052514-6/Pharm5.gif)
![Pharm6.gif](../images/052514/052514-6/Pharm6.gif)
![Pharm7.gif](../images/052514/052514-6/Pharm7.gif)
![Pharm8.gif](../images/052514/052514-6/Pharm8.gif)
![Pharm9.gif](../images/052514/052514-6/Pharm9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|